AstraZeneca (AZN) Given Buy Rating at Deutsche Bank

Deutsche Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research note released on Monday, December 11th.

Several other equities analysts have also recently commented on the stock. Shore Capital reissued a hold rating on shares of AstraZeneca in a research report on Monday, December 4th. Morgan Stanley reiterated an equal weight rating and issued a GBX 5,000 ($66.85) price objective on shares of AstraZeneca in a research note on Friday, December 1st. JPMorgan Chase & Co. set a GBX 4,800 ($64.18) price objective on shares of AstraZeneca and gave the company a neutral rating in a research note on Thursday, November 30th. Jefferies Group restated a hold rating and set a GBX 5,100 ($68.19) price target on shares of AstraZeneca in a research report on Thursday, November 16th. Finally, HSBC lifted their price objective on shares of AstraZeneca from GBX 4,340 ($58.03) to GBX 4,380 ($58.56) and gave the stock a reduce rating in a report on Thursday, November 16th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. AstraZeneca currently has a consensus rating of Hold and a consensus price target of GBX 5,200.82 ($69.54).

Shares of AstraZeneca (LON:AZN) traded down GBX 16 ($0.21) during trading hours on Monday, reaching GBX 5,105 ($68.26). The company had a trading volume of 2,292,932 shares, compared to its average volume of 1,730,000. AstraZeneca has a 1-year low of GBX 4,136.50 ($55.31) and a 1-year high of GBX 5,520 ($73.81). The firm has a market capitalization of $62,690.00 and a P/E ratio of 2,466.18.

COPYRIGHT VIOLATION WARNING: “AstraZeneca (AZN) Given Buy Rating at Deutsche Bank” was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.truebluetribune.com/2018/01/02/deutsche-bank-reaffirms-buy-rating-for-astrazeneca-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply